Join/Watch the weekly
TMAU UP Podcasts

MEBO Private Facebook Group
to join : contact
maria.delatorre@meboresearch.org

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact map@meboresearch.org

MEBO TMAU urine test

MEBO Research
TMAU Urine Test
United States only
PROGRAM IS PERMANENTLY SUSPENDED AS OF 2 MAY 2017

Click here for
REQUISITION FORM
Incomplete applications
will NOT be processed

SEE UPDATES HERE

1
test
$150 plus
shipping costs
2
tests
$250 plus
shipping costs

TWO PAYMENT PLAN OPTION
Send email to maria.delatorre@meboresearch.org to arrange, AFTER filling out Requisition Form, please.

Test analysis performed in batches of 20 or more

DATE: 2 MAY 2017
Currently on : PROGRAM IS TEMPORARILY SUSPENDED

Samples analyzed since June 2012 :
352
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect
BannerFans.com
RESEARCH DETAILS

DONATIONS THRU 31-NOV-2016:
£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14

MEBO UK PAYPAL FOR TRINZYME

********
MEBO US PAYPAL FOR TRINZYME

Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Friday, July 27, 2012

First western-world 'gene therapy' drug receives approval in Europe

Quote from UniQure press release

UniQure announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion that recommends marketing authorization of Glybera® (alipogene tiparvovec) as a treatment for lipoprotein lipase deficiency (LPLD) under exceptional circumstances.

gene therapy for genetic TMAU ?
Gene Therapy has been seen as a Holy Grail cure for metabolic disorders, especially disorders where a single enzyme is at fault. However since gene therapy stated to be researched between 10-20 years ago, not one drug has received approval in the western world by the appropriate regulatory bodies. Finally, a gene therapy drug has received approval in Europe, to become the first approved gene therapy drug in the western world.

The drug, Glybera, is for the rare metabolic disorder lipoprotein lipase deficiency, a disorder that currently has no alternative treatment.

The drug has been developed by UniQure in the Netherlands. The website says gene therapy is particularly suitable for single enzyme disorders, which would be the case for FMO3 deficiency and probably any other metabolic malodor disorders that have not been recorded yet.As well as already progressing in some trials for other rare metabolic disorders, they also expect it can treat other disorders such as Parkinson's disease and hearing loss, which UniQure are already investigating.

Below are some quotes regarding Glybera from the Uniqure press release

"First gene therapy in the Western world to reach important regulatory approval milestone, culminating 40 years of research"

"Validates uniQure’s unique AAV-based gene therapy platform, consisting of a modular, plug-and-play vector system and unrivaled GMP manufacturing capabilities on a commercial scale"

"After today’s positive recommendation, Glybera is poised to become the first in a class of gene therapy products approved in Europe to treat orphan diseases, rare conditions with a very high unmet medical need.” Marketing authorization covers all 27 European Union member states."

"Now, for the first time, a treatment exists for these patients that not only reduces this risk of getting severely sick, but also has a multi-year beneficial effect after just a single injection. The positive recommendation from the CHMP for Glybera therefore represents a major breakthrough for both LPLD patients and for medicine as a whole. Restoring the body's natural ability to break down fat particles in the blood in order to prevent pancreatitis and excruciating abdominal pain suffered by patients, is what gene therapy is all about: curing disease at the genetic level."

"At uniQure we are developing treatments for a number of other rare diseases as well, such as acute intermittent porphyria and Sanfilippo B. But the potential of gene therapy stretches far beyond rare diseases. As shown recently in a publication in the New England Journal of Medicine (N Engl J Med 2011; 365:2357-2365, December 22, 2011), hemophilia patients treated with our proprietary gene are showing a sustained clinical effect over several years, which has allowed prophylaxis treatment to be stopped. In addition, we are advancing programs in degenerative diseases such as Parkinson’s. We believe that just like antibodies, gene therapy will one day be a mainstay in clinical practice"

"The Company is now preparing to apply for regulatory approval in the US, Canada, and other markets."

"Data from these clinical trials indicate that a single dose administration of Glybera resulted in a long-term biological activity of the LPL protein."

Press Release on UniQure website

Links
NY Times article on Glybera being first western-world gene therapy drug to get approval

Glybera article in UK newspaper The Guardian

Gene therapy nears approval in Europe, BBC News Health

Gene therapy and stem cells unite, BBC News Health

1 comments:

Anonymous said...

more media links =)
http://www.bbc.co.uk/news/health-18926892

http://www.bbc.co.uk/news/health-15272081

Jul 29, 2012, 3:34:00 PM
Post a Comment